Biogen Inc. | Balance Sheet

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
1,223
1,845
3,429
4,895
3,689
3,538
Total Accounts Receivable
1,077
1,576
1,542
1,742
2,320
2,485
Inventories
659
804
893
1,002
903
930
Other Current Assets
226
447
837
1,093
962
688
Total Current Assets
3,185
4,673
6,700
8,732
7,873
7,641
Net Property, Plant & Equipment
1,751
1,766
2,188
2,502
3,182
3,601
Total Investments and Advances
683
1,527
2,856
2,929
3,143
2,733
Long-Term Note Receivable
17
13
6
-
-
-
Intangible Assets
5,743
5,789
6,749
7,478
8,512
8,826
Other Assets
485
549
1,006
1,236
942
334
Total Assets
11,863
14,317
19,505
22,877
23,653
25,289
ST Debt & Current Portion LT Debt
3
3
5
5
3
Accounts Payable
220
229
267
280
396
Income Tax Payable
-
168
209
232
68
Other Current Liabilities
1,535
1,819
2,097
2,904
2,901
Total Current Liabilities
1,758
2,220
2,578
3,420
3,368
Long-Term Debt
592
582
6,522
6,513
5,935
Provision for Risks & Charges
252
543
537
468
524
Deferred Taxes
233
51
125
93
123
Other Liabilities
407
107
369
255
1,105
Total Liabilities
3,242
3,503
10,130
10,748
11,055
Common Equity (Total)
8,620
10,809
9,373
12,140
12,613
Total Shareholders' Equity
8,620
10,809
9,373
12,140
12,613
Total Equity
8,621
10,814
9,375
12,129
12,598
Liabilities & Shareholders' Equity
11,863
14,317
19,505
22,877
23,653
Accumulated Minority Interest
1
5
2
12
15

About Biogen

View Profile
Address
225 Binney Street
Cambridge Massachusetts 02142
United States
Employees -
Website http://www.biogen.com
Updated 07/08/2019
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.